BioNTech (BNTX) Stock Chart - Revenue & Earnings | Quarter Chart

Select dashboard New custom dashboard
Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0500M1B2B2B2B3B4B4BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
012253850627588100Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesSelling And Marketing ExpensesGeneral And Administrative ExpensesOther Expenses
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-700M-588M-475M-362M-250M-138M-25M88M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

Revenue Variation (%)

Revenue Variation
-100-1275162250338425512600Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
02505007501K1K2K2K2KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
-40-10205080110140170200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-200-175-150-125-100-74-49-241Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
050100150200250300350400Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
050M100M150M200M250M300M350M400MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
012345678Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
0375M750M1B2B2B2B3B3BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Balance Sheet

Current Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Quick Ratio

Total AssetsTotal Liabilities
05B10B15B20B25B30B35B40BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash & Equivalents

Total Current AssetsTotal Non Current Assets
04B8B11B15B19B22B26B30BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Assets

Total Current LiabilitiesTotal Non Current Liabilities
0500M1B2B2B2B3B4B4BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Liabilities

Total Stockholders Equity
04B8B11B15B19B22B26B30BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Shareholders Equity

Debt To Equity
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Asset Composition

Cash And Cash EquivalentsShort Term Investments
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Debt Structure

Short Term DebtLong Term Debt
050M100M150M200M250M300M350M400MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Key Metrics

BioNTech (BNTX) quarterly earnings & revenue

BioNTech (BNTX) reported revenue of $139.73M for Q1 2026, down 34.3% year-over-year, with net income of $-629.33M and diluted EPS of $-2.49.

Over the last four reported quarters, BioNTech generated $3.26B in revenue and $-1.46B in net income.

BioNTech's next earnings report is scheduled for August 4, 2026 before market open; analysts estimate EPS of $-2.40.

BioNTech quarterly results

Fiscal quarterRevenueRevenue YoYNet incomeEPS (diluted)
Q1 2026$139.73M-34.3%$-629.33M$-2.49
Q4 2025$1.05B-24.5%$-351.70M$-1.43
Q3 2025$1.77B+22.0%$-33.41M$-0.14
Q2 2025$303.58M+102.6%$-450.02M$-1.86
Q1 2025$212.79M-2.6%$-484.01M$-2.01
Q4 2024$1.39B-19.5%$302.07M$1.26
Q3 2024$1.45B+39.0%$230.60M$0.94
Q2 2024$149.81M-23.3%$-940.31M$-3.98

📈 Analysts estimate BNTX EPS of $-2.40 for the upcoming quarter. See BioNTech revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

BioNTech (BNTX) — frequently asked questions

When does BioNTech (BNTX) report earnings next?

BioNTech is expected to report earnings on August 4, 2026 before market open. Analysts estimate EPS of $-2.40.

What was BNTX's revenue last quarter?

BioNTech reported revenue of $139.73M in Q1 2026, down 34.3% from the same quarter a year earlier.

What was BNTX's EPS last quarter?

BioNTech reported diluted EPS of $-2.49 in Q1 2026.

Is BioNTech profitable?

BioNTech is currently not profitable, with $-1.46B in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)